171 related articles for article (PubMed ID: 12384515)
1. p300 mediates androgen-independent transactivation of the androgen receptor by interleukin 6.
Debes JD; Schmidt LJ; Huang H; Tindall DJ
Cancer Res; 2002 Oct; 62(20):5632-6. PubMed ID: 12384515
[TBL] [Abstract][Full Text] [Related]
2. Activation of p300 histone acetyltransferase activity and acetylation of the androgen receptor by bombesin in prostate cancer cells.
Gong J; Zhu J; Goodman OB; Pestell RG; Schlegel PN; Nanus DM; Shen R
Oncogene; 2006 Mar; 25(14):2011-21. PubMed ID: 16434977
[TBL] [Abstract][Full Text] [Related]
3. Changes in androgen receptor nongenotropic signaling correlate with transition of LNCaP cells to androgen independence.
Unni E; Sun S; Nan B; McPhaul MJ; Cheskis B; Mancini MA; Marcelli M
Cancer Res; 2004 Oct; 64(19):7156-68. PubMed ID: 15466214
[TBL] [Abstract][Full Text] [Related]
4. p300 regulates androgen receptor-independent expression of prostate-specific antigen in prostate cancer cells treated chronically with interleukin-6.
Debes JD; Comuzzi B; Schmidt LJ; Dehm SM; Culig Z; Tindall DJ
Cancer Res; 2005 Jul; 65(13):5965-73. PubMed ID: 15994976
[TBL] [Abstract][Full Text] [Related]
5. p300 in prostate cancer proliferation and progression.
Debes JD; Sebo TJ; Lohse CM; Murphy LM; Haugen DA; Tindall DJ
Cancer Res; 2003 Nov; 63(22):7638-40. PubMed ID: 14633682
[TBL] [Abstract][Full Text] [Related]
6. Vasoactive intestinal peptide transactivates the androgen receptor through a protein kinase A-dependent extracellular signal-regulated kinase pathway in prostate cancer LNCaP cells.
Xie Y; Wolff DW; Lin MF; Tu Y
Mol Pharmacol; 2007 Jul; 72(1):73-85. PubMed ID: 17430995
[TBL] [Abstract][Full Text] [Related]
7. Androgen deprivation increases p300 expression in prostate cancer cells.
Heemers HV; Sebo TJ; Debes JD; Regan KM; Raclaw KA; Murphy LM; Hobisch A; Culig Z; Tindall DJ
Cancer Res; 2007 Apr; 67(7):3422-30. PubMed ID: 17409453
[TBL] [Abstract][Full Text] [Related]
8. Identification and characterization of androgen receptor associated coregulators in prostate cancer cells.
Sampson ER; Yeh SY; Chang HC; Tsai MY; Wang X; Ting HJ; Chang C
J Biol Regul Homeost Agents; 2001; 15(2):123-9. PubMed ID: 11501969
[TBL] [Abstract][Full Text] [Related]
9. Constitutive activation of nuclear factor kappaB p50/p65 and Fra-1 and JunD is essential for deregulated interleukin 6 expression in prostate cancer.
Zerbini LF; Wang Y; Cho JY; Libermann TA
Cancer Res; 2003 May; 63(9):2206-15. PubMed ID: 12727841
[TBL] [Abstract][Full Text] [Related]
10. Histone acetyltransferase activity of p300 enhances the activation of IL-12 p40 promoter.
Sun H; Lu J; Wei L; Wang X; Xu X; Dong M; Huang B
Mol Immunol; 2004 Nov; 41(12):1241-6. PubMed ID: 15482860
[TBL] [Abstract][Full Text] [Related]
11. Androgen axis in prostate cancer.
Culig Z; Bartsch G
J Cell Biochem; 2006 Oct; 99(2):373-81. PubMed ID: 16598769
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of interleukin-6 with CNTO328, an anti-interleukin-6 monoclonal antibody, inhibits conversion of androgen-dependent prostate cancer to an androgen-independent phenotype in orchiectomized mice.
Wallner L; Dai J; Escara-Wilke J; Zhang J; Yao Z; Lu Y; Trikha M; Nemeth JA; Zaki MH; Keller ET
Cancer Res; 2006 Mar; 66(6):3087-95. PubMed ID: 16540658
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of MAPK-signaling pathway promotes the interaction of the corepressor SMRT with the human androgen receptor and mediates repression of prostate cancer cell growth in the presence of antiandrogens.
Eisold M; Asim M; Eskelinen H; Linke T; Baniahmad A
J Mol Endocrinol; 2009 May; 42(5):429-35. PubMed ID: 19223455
[TBL] [Abstract][Full Text] [Related]
14. Activation of mitogen-activated protein kinase pathway by the antiandrogen hydroxyflutamide in androgen receptor-negative prostate cancer cells.
Lee YF; Lin WJ; Huang J; Messing EM; Chan FL; Wilding G; Chang C
Cancer Res; 2002 Nov; 62(21):6039-44. PubMed ID: 12414626
[TBL] [Abstract][Full Text] [Related]
15. Interleukin-4 in patients with prostate cancer.
Takeshi U; Sadar MD; Suzuki H; Akakura K; Sakamoto S; Shimbo M; Suyama T; Imamoto T; Komiya A; Yukio N; Ichikawa T
Anticancer Res; 2005; 25(6C):4595-8. PubMed ID: 16334148
[TBL] [Abstract][Full Text] [Related]
16. Regulator of G-protein signaling 2 (RGS2) inhibits androgen-independent activation of androgen receptor in prostate cancer cells.
Cao X; Qin J; Xie Y; Khan O; Dowd F; Scofield M; Lin MF; Tu Y
Oncogene; 2006 Jun; 25(26):3719-34. PubMed ID: 16449965
[TBL] [Abstract][Full Text] [Related]
17. Short hairpin RNA knockdown of the androgen receptor attenuates ligand-independent activation and delays tumor progression.
Cheng H; Snoek R; Ghaidi F; Cox ME; Rennie PS
Cancer Res; 2006 Nov; 66(21):10613-20. PubMed ID: 17079486
[TBL] [Abstract][Full Text] [Related]
18. Selective role of an NH2-terminal WxxLF motif for aberrant androgen receptor activation in androgen depletion independent prostate cancer cells.
Dehm SM; Regan KM; Schmidt LJ; Tindall DJ
Cancer Res; 2007 Oct; 67(20):10067-77. PubMed ID: 17942941
[TBL] [Abstract][Full Text] [Related]
19. Down-regulation of p300/CBP histone acetyltransferase activates a senescence checkpoint in human melanocytes.
Bandyopadhyay D; Okan NA; Bales E; Nascimento L; Cole PA; Medrano EE
Cancer Res; 2002 Nov; 62(21):6231-9. PubMed ID: 12414652
[TBL] [Abstract][Full Text] [Related]
20. Alpha-methylacyl-CoA racemase as an androgen-independent growth modifier in prostate cancer.
Zha S; Ferdinandusse S; Denis S; Wanders RJ; Ewing CM; Luo J; De Marzo AM; Isaacs WB
Cancer Res; 2003 Nov; 63(21):7365-76. PubMed ID: 14612535
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
